EX-10.3





 Exhibit 10.3 

SECURITIES PURCHASE AGREEMENT 

THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April     , 2019, is entered into by
and between MATEON THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the individuals identified on the signature page hereto (each a “Buyer” and collectively, the “Buyers”). 

WITNESSETH: 

WHEREAS, the Company and the Buyers are executing and delivering this Agreement in accordance with and in reliance upon the exemption
from securities registration afforded, inter alia, by Rule 506 under Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended
(the “1933 Act”), and/or Section 4(2) of the 1933 Act; and 
 WHEREAS, the Buyers wish to purchase from the Company,
and the Company wishes to sell to the Buyers, upon the terms and subject to the conditions of this Agreement, securities consisting of the Company’s Convertible Debentures due three years from the respective dates of issuance (the
“Debentures”), each of which are in the form of Exhibit A hereto, which will be convertible into shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), in the aggregate principal amount
of up to Four Hundred Thousand and 00/100 Dollars ($400,000.00), for an aggregate Purchase Price of up to Three Hundred Sixty Thousand and 00/100 Dollars ($360,000.00), all upon the terms and subject to the conditions of this Agreement, the
Debentures, and other related documents; 
 NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein
and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
DEFINITIONS; AGREEMENT TO PURCHASE. 
 a. Certain Definitions. As used herein, each of the following terms has the meaning set
forth below, unless the context otherwise requires: 
 (i) “Affiliate” means, with respect to a specific Person referred to in the
relevant provision, another Person who or which controls or is controlled by or is under common control with such specified Person. 
 (ii)
“Certificates” means certificates representing the Conversion Shares issuable hereunder, each duly executed on behalf of the Company and issued hereunder. 

(iii) “Closing Date” means the date on which one of the two (2) Closings are held, which are the Signing Closing Date and the
Second Closing Date. 
 (iv) [Intentionally Omitted]. 












 (v) [Intentionally Omitted]. 

(vi) “Common Stock” shall have the meaning ascribed to such term in the Recitals. 

(vii) “Conversion Amount” shall mean the Conversion Amount as defined in the Debentures. 

(viii) “Conversion Price” means the Conversion Price as defined in the Debentures. 

(ix) “Conversion Shares” means the shares of Common Stock issuable upon conversion of the Debentures. 

(x) “DWAC Operational” means that the Common Stock is eligible for clearing through the Depository Trust Company (“DTC”)
via the DTC’s Deposit Withdrawal Agent Commission or “DWAC” system and active and in good standing for DWAC issuance by the Transfer Agent (as defined herein). 

(xi) “Dollars” or “$” means United States Dollars. 

(xii) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(xiii) [Intentionally Omitted]. 

(xiv) [Intentionally Omitted]. 

(xv) “Market Price of the Common Stock” means (x) the closing bid price of the Common Stock for the period indicated in the
relevant provision hereof (unless a different relevant period is specified in the relevant provision), as reported by Bloomberg, LP or, if not so reported, as reported on the OTCQB, OTCQX or OTC Pink or (y) if the Common Stock is listed on a
stock exchange, the closing price on such exchange, as reported by Bloomberg LP. 
 (xvi) “Material Adverse Effect” means a
material adverse effect on the business, operations or condition (financial or otherwise) or results of operation of the Company and its Subsidiaries taken as a whole, in the reasonable commercial discretion of the Buyer, irrespective of any finding
of fault, magnitude of liability (or lack of financial liability). Without limiting the generality of the foregoing, the occurrence of any of the following, in the reasonable commercial discretion of a Buyer, shall be considered a Material Adverse
Effect: (i) any final money, judgment, writ or warrant of attachment, or similar process (including an arbitral determination) in excess of Fifty Thousand Dollars ($50,000) shall be entered or filed against the Company or any of its
Subsidiaries (including, in any event, products liability claims against the Company or its Subsidiaries), (ii) the suspension or withdrawal of any governmental authority or permit pertaining to a material amount of the Company’s or any
Subsidiary’s products or services, (iii) the loss of any material insurance coverage (including, in any case, comprehensive general liability coverage, products liability coverage or directors and officers coverage, in each case in effect
at the time of execution and delivery of this Agreement), (iv) an action by a regulatory agency or 

  
 2 













 
governmental body affecting the Common Stock (including, without limitation, (1) the commencement of any regulatory investigation of which the Company is aware, the suspension of trading of
the Common Stock by the Financial Industry Regulation Authority (“FINRA”), the SEC, the OTC Bulletin Board (“OTCBB”) or the OTC Markets Group, Inc., the failure of the Common Stock to be DTC eligible or the placing of the Common
Stock on the DTC “chill list” or (2) the engaging in any market manipulation or other unlawful or improper trading or other activity by any Affiliate), (v) the Company’s independent registered accountants shall resign under
circumstances where a disagreement exists between the Company and its independent registered accountants, or (vi) the Company shall fail to timely file any disclosure document as required by applicable federal or state securities laws and
regulations when due (including extensions) or by the rules and regulations of any exchange, trading market or quotation system to which the Company or the Common Stock is subject. 

(xvii) “Person” means any living person or any entity, such as, but not necessarily limited to, a corporation, partnership or trust.

 (xviii) “Purchase Price” means the price that a Buyer pays for the Debentures at each respective Closing, which are the Signing
Purchase Price and the Second Purchase Price, as the case may be. 
 (xix) “Registrable Securities” shall mean the Conversion
Shares and, to the extent applicable, and any other shares of capital stock or other securities of the Company or any successor to the Company that are issued upon exchange of Conversion Shares and/or such Restricted Stock. 

(xx) “Registration Statement” shall mean a registration statement on Form S-1 (or any successor thereto) filed or contemplated to be
filed by the Company with the SEC under the Securities Act. 
 (xxi) “Restricted Stock” shall mean shares of Common Stock which are
not freely trading shares when issued. 
 (xxii) “Securities” means the Debentures and the Shares. 

(xxiii) “Shares” means the Conversion Shares. 

(xxiv) “Second Closing Date” shall have the meaning ascribed to such term in Section 6(b). 

(xxv) “Second Debenture” means the second of the two (2) tranches of Debentures, in the aggregate principal amount of Two
Hundred Thousand and 00/100 Dollars ($200,000.00), which is issued by the Company to the Buyers on the Second Closing Date. 
 (xxvi)
“Second Purchase Price” shall be an aggregate of One Hundred Eighty Thousand and 00/100 Dollars ($180,000.00). 

  
 3 













 (xxvii) “Signing Closing Date” shall have the meaning ascribed to such term in
Section 6(a). 
 (xxviii) “Signing Debenture” means the first of the two (2) tranches of Debentures, in the aggregate
principal amount of Two Hundred Thousand and 00/100 Dollars ($200,000.00), to be issued by the Company to the Buyers on the Signing Closing Date. 

(xxix) “Signing Purchase Price” shall be an aggregate of One Hundred Eighty Thousand and 00/100 Dollars ($180,000.00). 

(xxx) “Subsidiary” shall have the meaning ascribed to such term in Section 3(b). 

(xxxi) [Intentionally Omitted]. 

(xxxii) [Intentionally Omitted]. 

(xxxiii) [Intentionally Omitted]. 

(xxxiv) “Transaction Documents” means, collectively, this Agreement, the Debentures, and the other agreements, documents and
instruments contemplated hereby or thereby. 
 (xxxv) “Transfer Agent” shall have the meaning ascribed to such term in
Section 4(a). 
 (xxxvi) [Intentionally Omitted]. 

b. Purchase and Sale of Debentures. 

(i) The Buyers, severally and not jointly, agree to purchase from the Company, and the Company agrees to sell to the Buyer, the Debentures on
the terms and conditions set forth below in this Agreement and the other Transaction Documents. 
 (ii) Subject to the terms and conditions
of this Agreement and the other Transaction Documents, the Buyers will purchase the Debentures at certain closings (each, a “Closing”) to be held on certain respective Closing Dates. 

c. [Reserved] 
 (i)
[Reserved] 
 (ii) [Reserved] 

2. BUYER’S REPRESENTATIONS, WARRANTIES, ETC. 

Each Buyer, severally and not jointly represents and warrants to, and covenants and agrees with, the Company as follows: 

  
 4 













 a. Investment Purpose. Without limiting the Buyer’s right to sell the Shares
pursuant to a Registration Statement, the Buyer is purchasing the Debentures, and will be acquiring the Conversion Shares, for its own account for investment only and not with a view towards the public sale or distribution thereof and not with a
view to or for sale in connection with any distribution thereof. 
 b. Accredited Investor Status. The Buyer is (i) an
“accredited investor” as that term is defined in Rule 501 of the General Rules and Regulations under the 1933 Act by reason of Rule 501(a)(3), (ii) experienced in making investments of the kind described in this Agreement and the
related documents, (iii) able, by reason of the business and financial experience of its officers (if an entity) and professional advisors (who are not affiliated with or compensated in any way by the Company or any of its affiliates or selling
agents), to protect its own interests in connection with the transactions described in this Agreement, and the related documents, and (iv) able to afford the entire loss of its investment in the Securities. 

c. Subsequent Offers and Sales. All subsequent offers and sales of the Securities by the Buyer shall be made pursuant to registration of
the Shares under the 1933 Act or pursuant to an exemption from registration and compliance with applicable states’ securities laws. 

d. Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities. 

e. Information. The Buyer and its advisors have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer. The Buyer and its advisors have been afforded the opportunity to ask questions of the Company and have received complete and
satisfactory answers to any such inquiries. Without limiting the generality of the foregoing, the Buyer has also had the opportunity to obtain and to review the Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2018 (collectively, the “SEC Documents”). 
 f. Investment Risk. The Buyer understands that its investment in the securities
constitutes high risk investment, its investment in the Securities involves a high degree of risk, including the risk of loss of the Buyer’s entire investment. 

g. Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities. 

  
 5 













 h. Organization; Authorization. The Buyer, if an entity, is duly organized, validly
existing and in good standing under the laws of the jurisdiction of its organization. This Agreement and the other Transaction Documents have been duly and validly authorized, executed and delivered on behalf of the Buyer and create a valid and
binding agreement of the Buyer enforceable in accordance with its terms, subject as to enforceability to general principles of equity and to bankruptcy, insolvency, moratorium and other similar laws affecting the enforcement of creditors’
rights generally. 
 i. Residency. The state in which any offer to sell Securities hereunder was made to or accepted by the Buyer is
the state shown as the Buyer’s address contained herein, and the Buyer is a resident of such state only. 
 3. COMPANY
REPRESENTATIONS AND WARRANTIES, ETC. 
 The Company represents and warrants to each Buyer that: 

a. Concerning the Debentures and the Shares. There are no preemptive rights of any stockholder of the Company to acquire the Debentures
or the Shares. 
 b. Organization; Subsidiaries; Reporting Company Status. Attached hereto as Schedule 3(b) is an
organizational chart describing all of the Company’s wholly-owned and majority-owned subsidiaries (the “Subsidiaries”) and other Affiliates, including the relationships among the Company and such Subsidiaries, including as to each
Subsidiary its jurisdiction of organization and the percentage of ownership held by the Company, and the parent company of the Subsidiary, including the percentage of ownership of the Company held by it. The Company and each Subsidiary is a
corporation or other form of businesses entity duly organized, validly existing and in good standing under the laws its respective jurisdiction of organization, and each of them has the requisite corporate or other power to own its properties and to
carry on its business as now being conducted. The Company and each Subsidiary is duly qualified as a foreign corporation or other entity to do business and is in good standing in each jurisdiction where the nature of the business conducted or
property owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have a Material Adverse Effect. The Common Stock is listed and traded on the OTCM (as defined below) (trading
symbol: MATN). The Company has received no notice, either oral or written, from FINRA, the SEC, or any other organization, with respect to the continued eligibility of the Common Stock for such listing, and the Company has maintained all
requirements for the continuation of such listing. The Company is an operating company in that, among other things (A) it primarily engages, wholly or substantially, directly or indirectly through a majority owned Subsidiary or Subsidiaries, in
the production or sale, or the research or development, of a product or service other than the investment of capital, (B) it is not an individual or sole proprietorship, (C) it is not an entity with no specific business plan or purpose and
its business plan is not to engage in a merger or acquisition with an unidentified company or companies or other entity or person, and (D) it intends to use the proceeds from the sale of the Debentures solely for the operation of the
Company’s business and uses other than personal, family, or household purposes. 
 c. Authorized Shares. Schedule
3(c) sets forth all capital stock and derivative securities of the Company that are authorized for issuance and that are issued and outstanding. All issued and outstanding shares of Common Stock have been duly authorized and validly issued and
are fully paid and nonassessable. The Shares have been duly authorized and, when issued upon conversion of, or as interest on, the Debentures, the Shares will be duly and validly issued, fully paid and non-assessable and will not subject the holder
thereof to personal liability by reason of being such holder. 

  
 6 













 d. Authorization. This Agreement, the issuance of the Debentures (including without
limitation the incurrence of indebtedness thereunder), the issuance of the Conversion Shares under the Debentures, and the other transactions contemplated by the Transaction Documents, have been duly, validly and irrevocably authorized by the
Company, and this Agreement has been duly executed and delivered by the Company. The Company’s board of directors, in the exercise of its fiduciary duties, has irrevocably approved the entry into and performance of the Transaction Documents,
including, without limitation the sale of the Debentures and the issuance of Conversion Shares, based upon a reasonable inquiry concerning the Company’s financing objectives and financial situation. Each of the Transaction Documents, when
executed and delivered by the Company, are and will be, valid, legal and binding agreements of the Company, enforceable in accordance with their respective terms, subject as to enforceability to general principles of equity and to bankruptcy,
insolvency, moratorium, and other similar laws affecting the enforcement of creditors’ rights generally. 
 e. Non-contravention.
The execution and delivery of the Transaction Documents, the issuance of the Securities and the consummation by the Company of the other transactions contemplated by this Agreement and the Debentures (including without limitation the incurrence of
indebtedness thereunder) do not and will not conflict with or result in a breach by the Company of any of the terms or provisions of, or constitute a default under (i) the articles of incorporation or by-laws of the Company, each as currently
in effect, (ii) any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or by which it or any of its properties or assets are bound, including any listing agreement for the Common Stock,
except as herein set forth or an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the triggering of any anti-dilution rights, rights of first refusal or first offer on the part of holders of
the Company’s securities, (iii) to its knowledge, any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal or state regulatory body, administrative agency, or other
governmental body having jurisdiction over the Company or any of its properties or assets, or (iv) the Company’s listing agreement for its Common Stock (if applicable). 

f. Approvals. No authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or
stock exchange or market or the stockholders of the Company is required to be obtained by the Company for the entering into and performing this Agreement and the other Transaction Documents (including without limitation the issuance and sale of the
Securities to the Buyer as contemplated by this Agreement) except such authorizations, approvals and consents that have been obtained, or such authorizations, approvals and consents, the failure of which to obtain would not have a Material Adverse
Effect. 
 g. SEC Filings; Rule 144 Status. None of the SEC Documents contained, at the time they were filed, any untrue statement of
a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein in light of the circumstances under which they were made, not misleading. The Company has timely filed all 

  
 7 













 
requisite forms, reports and exhibits thereto with the SEC as required, including extensions of time pursuant to Rule 12b-25 of the Exchange Act where applicable. The Company is not aware of any
event occurring on or prior to the execution and delivery of this Agreement that would require the filing of, or with respect to which the Company intends to file, a Form 8-K after such time. The Company satisfies the requirements of Rule 144(i)(2),
and the Company shall continue to satisfy all applicable requirements of Rule 144 (or any successor thereto) for so long as any Securities are outstanding and not registered pursuant to an effective registration statement filed with the SEC. 

h. Absence of Certain Changes. Since December 31, 2018, when viewed from the perspective of the Company and its Subsidiaries taken
as a whole, there has been no material adverse change and no material adverse development in the business, properties, operations, condition (financial or otherwise), or results of operations of the Company and its Subsidiaries (including, without
limitation, a change or development which constitutes, or with the passage of time is reasonably likely to become, a Material Adverse Effect), except as disclosed in the SEC Documents. Since December 31, 2018, except as provided in the SEC
Documents, the Company has not (i) incurred or become subject to any material liabilities (absolute or contingent) except liabilities incurred in the ordinary course of business consistent with past practices; (ii) discharged or satisfied
any material lien or encumbrance or paid any material obligation or liability (absolute or contingent), other than current liabilities paid in the ordinary course of business consistent with past practices; (iii) declared or made any payment or
distribution of cash or other property to stockholders with respect to its capital stock, or purchased or redeemed, or made any agreements to purchase or redeem, any shares of its capital stock; (iv) sold, assigned or transferred any other
tangible assets, or canceled any debts or claims, except in the ordinary course of business consistent with past practices; (v) suffered any substantial losses or waived any rights of material value, whether or not in the ordinary course of
business, or suffered the loss of any material amount of existing business; (vi) made any changes in employee compensation, except in the ordinary course of business consistent with past practices; or (vii) experienced any material
problems with labor or management in connection with the terms and conditions of their employment. 
 i. Full Disclosure. There is no
fact known to the Company (other than general economic conditions known to the public generally or as disclosed in the SEC Documents) that has not been disclosed in writing to the Buyer that (i) would reasonably be expected to have a Material
Adverse Effect, (ii) would reasonably be expected to materially and adversely affect the ability of the Company to perform its obligations pursuant to the Transaction Documents, or (iii) would reasonably be expected to materially and
adversely affect the value of the rights granted to the Buyers in the Transaction Documents. 
 j. Absence of Litigation. Except as
described in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board or body pending or, to the knowledge of the Company, threatened against or affecting the Company, wherein an
unfavorable decision, ruling or finding would have a Material Adverse Effect or which would adversely affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, any of the Transaction
Documents. The Company is not a party to or subject to the provisions of, any order, writ, injunction, judgment or decree of any court or government agency or instrumentality which could reasonably be expected to have a Material Adverse Effect. 


  
 8 













 k. Absence of Liens. The Company’s assets are not encumbered by any liens or
mortgages except as described in the SEC Documents. 
 l. Absence of Events of Default. No event of default (or its equivalent term),
as defined in the respective agreement, indenture, mortgage, deed of trust or other instrument, to which the Company is a party, and no event which, with the giving of notice or the passage of time or both, would become an event of default (or its
equivalent term) (as so defined in such document), has occurred and is continuing, which would have a Material Adverse Effect. 
 m. No
Undisclosed Liabilities or Events. The Company has no liabilities or obligations other than those disclosed in the SEC Documents or those incurred in the ordinary course of the Company’s business since December 31, 2018, and which
individually or in the aggregate, do not or would not have a Material Adverse Effect. No event or circumstances has occurred or exists with respect to the Company or its properties, business, condition (financial or otherwise), or results of
operations, which, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed. There are no proposals currently under
consideration or currently anticipated to be under consideration by the Board of Directors or the executive officers of the Company which proposal would (x) change the articles of incorporation, by-laws or any other charter document of the
Company, each as currently in effect, with or without shareholder approval, which change would reduce or otherwise adversely affect the rights and powers of the shareholders of the Common Stock or (y) materially or substantially change the
business, assets or capital of the Company. 
 n. No Integrated Offering. Neither the Company nor any of its affiliates nor any Person
acting on its or their behalf has, directly or indirectly, at any time during the six month period immediately prior to the date of this Agreement made any offer or sales of any security or solicited any offers to buy any security under
circumstances that would eliminate the availability of the exemption from registration under Rule 506 of Regulation D in connection with the offer and sale of the Securities as contemplated hereby. 

o. Dilution. The number of Shares issuable upon conversion of the Debentures may increase substantially in certain circumstances,
including, but not necessarily limited to, the circumstance wherein the Market Price of the Common Stock declines prior to the conversion of the Debentures. The Company’s executive officers and directors fully understand the nature of the
securities being sold hereby and recognize that they have a potential dilutive effect and further that the conversion of the Debentures and/or sale of the Conversion Shares may have an adverse effect on the Market Price of the Common Stock. The
Board of Directors of the Company has concluded, in its good faith business judgment that such issuance is in the best interests of the Company. The Company specifically acknowledges that its obligation to issue the Conversion Shares upon conversion
of the Debentures is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership percentages of other shareholders of the Company. 

  
 9 













 p. Regulatory Permits. The Company has all such permits, easements, consents,
licenses, franchises and other governmental and regulatory authorizations from all appropriate federal, state, local or other public authorities (“Permits”) as are necessary to own and lease its properties and conduct its businesses in all
material respects in the manner described in the SEC Documents and as currently being conducted. All such Permits are in full force and effect and the Company has fulfilled and performed all of its material obligations with respect to such Permits,
and no event has occurred that allows, or after notice or lapse of time would allow, revocation or termination thereof or will result in any other material impairment of the rights of the holder of any such Permit, subject in each case to such
qualification as may be disclosed in the SEC Documents. Such Permits contain no restrictions that would materially impair the ability of the Company to conduct business in the manner consistent with its past practices. The Company has not received
notice or otherwise has knowledge of any proceeding or action relating to the revocation or modification of any such Permit. 
 q.
[Intentionally Omitted]. 
 r. Hazardous Materials. The Company is in compliance with all applicable Environmental Laws in all
respects except where the failure to comply does not have and could not reasonably be expected to have a Material Adverse Effect. For purposes of the foregoing: 

“Environmental Laws” means, collectively, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as
amended, the Superfund Amendments and Reauthorization Act of 1986, the Resource Conservation and Recovery Act, the Toxic Substances Control Act, as amended, the Clean Air Act, as amended, the Clean Water Act, as amended, any other
“Superfund” or “Superlien” law or any other applicable federal, state or local statute, law, ordinance, code, rule, regulation, order or decree regulating, relating to, or imposing liability or standards of conduct concerning,
the environment or any Hazardous Material. 
 “Hazardous Material” means and includes any hazardous, toxic or dangerous
waste, substance or material, the generation, handling, storage, disposal, treatment or emission of which is subject to any Environmental Law. 

s. Independent Public Accountants. The Company’s auditor is an independent registered public accounting firm with respect to the
Company, as required by the 1933 Act, the Exchange Act and the rules and regulations promulgated thereunder. 
 t. Internal Accounting
Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that (1) transactions are executed in accordance with management’s general or specific authorization;
(2) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (3) access to assets is permitted only in
accordance with management’s general or specific authorization; and (4) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

  
 10 













 u. Brokers. No Person (other than the Buyer and its principals, employees and agents)
is entitled to receive any consideration from the Company or the Buyer arising from any finder’s agreement, brokerage agreement or other agreement to which the Company is a party. 

v. DWAC Operational; DRS. The Company is currently and shall remain DWAC Operational and eligible for DRS. 

4. CERTAIN COVENANTS AND ACKNOWLEDGMENTS. 

a. Transfer Restrictions. The parties acknowledge and agree that (1) the Debentures have not been registered under the provisions
of the 1933 Act and the Shares have not been registered under the 1933 Act, and may not be transferred unless (A) subsequently registered thereunder or (B) the Securities to be sold or transferred may be sold or transferred pursuant to an
exemption from such registration; (2) any sale of the Securities made in reliance on Rule 144 promulgated under the 1933 Act (“Rule 144”) may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not
applicable, any resale of such Securities under circumstances in which the seller, or the Person through whom the sale is made, may be deemed to be an underwriter, as that term is used in the 1933 Act, may require compliance with some other
exemption under the 1933 Act or the rules and regulations of the SEC thereunder, (3) at the request of a Buyer, the Company shall, from time to time, within two (2) business days of such request, at the sole cost and expense of the
Company, either (i) deliver to its transfer agent and registrar for the Common Stock (the “Transfer Agent”) a written letter instructing and authorizing the Transfer Agent to process transfers of the Shares at such time as the Buyer
has held the Securities for the minimum holding period permitted under Rule 144, subject to the Buyer’s providing to the Transfer Agent certain customary representations contemporaneously with any requested transfer, or (ii) at the
Buyer’s option or if the Transfer Agent requires further confirmation of the availability of an exemption from registration, furnish to the Buyer an opinion of the Company’s counsel in favor of the Buyer (and, at the request of the Buyer,
any agent of the Buyer, including but not limited to the Buyer’s broker or clearing firm) and the Transfer Agent, reasonably satisfactory in form, scope and substance to the Buyer and the Transfer Agent, to the effect that a contemporaneously
requested transfer of shares does not require registration under the 1933 Act, pursuant to the 1933 Act, Rule 144 or other regulations promulgated under the 1933 Act and (4) neither the Company nor any other Person is under any obligation to
register the Securities (other than pursuant to this Agreement) under the 1933 Act or to comply with the terms and conditions of any exemption thereunder. 

b. Restrictive Legend. Each Buyer acknowledges and agrees that the Debentures, and, until such time as the Shares have been registered
under the 1933 Act as contemplated hereby and sold in accordance with an effective Registration Statement, certificates and other instruments representing any of the Securities shall bear a restrictive legend in substantially the following form (and
a stop-transfer order may be placed against transfer of any such Securities): 

  
 11 













 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED
BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. 
 c.
Piggy-Back Registration Rights. From and after the Signing Closing Date and until eighteen (18) months after the Signing Closing Date, if the Company contemplates making an offering of Common Stock (or other equity securities convertible
into or exchangeable for Common Stock) registered for sale under the Securities Act or proposes to file a Registration Statement covering any of its securities, the Company shall at each such time give prompt written notice to each Buyer of its
intention to do so and of the registration rights granted under this Agreement. Upon the written request of a Buyer made within thirty (30) days after the receipt of any such notice (which request shall specify the Registrable Securities
intended to be disposed of by such Buyer and the intended method of disposition thereof), the Company shall, at its sole cost and expense, use its best efforts to effect the registration of all Registrable Securities which the Company has been so
requested to register each Buyer, to the extent requisite to permit the disposition (in accordance with the intended methods of disposition) of the Registrable Securities each Buyer, by inclusion of such Registrable Securities in the Registration
Statement which covers the securities which the Company proposes to register; provided, that if the Company is unable to register the full amount of Registrable Securities in an “at the market offering” under SEC rules and regulations due
to the high percentage of the Company’s Common Stock the Registrable Securities represents (giving effect to all other securities being registered in the Registration Statement), then the Company may reduce, on a pro rata basis, the amount of
Registrable Securities subject to the Registration Statement to a lesser amount which equals the maximum number of Registrable Securities that the Company is permitted to register in an “at the market offering”; and provided, further, that
if, at any time after giving written notice of its intention to register any Registrable Securities and prior to the effective date of the Registration Statement filed in connection with such registration, the Company shall determine for any reason
either not to register or to delay registration of such Registrable Securities, the Company may, at its election, give written notice of such determination to each Buyer and, thereupon, (i) in the case of a determination not to register, the
Company shall be relieved of its obligation to register any Registrable Securities in connection with such registration (but not from its obligation to pay the expenses of registration in connection therewith), and (ii) in the case of a
determination to delay registering such Registrable Securities, shall be permitted to delay registering any Registrable Securities, for the same period as the delay in registering such other securities. If a Buyer shall have transferred all or part
of its Registrable Securities, then for purposes of this Section, the term “Buyer” shall reference Buyer and/or such transferee(s). 

  
 12 













 d. Securities Filings. The Company undertakes and agrees to make all necessary
filings (including, without limitation, a Form D) in connection with the sale of the Securities to each Buyer required under any United States laws and regulations applicable to the Company (including without limitation state “blue sky”
laws), or by any domestic securities exchange or trading market, and to provide a copy thereof to each Buyer promptly after such filing. 

e. Reporting Status; Public Trading Market; DTC Eligibility. So long as a Buyer beneficially own any Securities, (i) the Company
shall timely file, prior to or on the date when due, all reports that would be required to be filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act if the Company had securities registered under Section 12(b) or 12(g) of
the Exchange Act; (ii) the Company shall not be operated as, or report, to the SEC or any other Person, that the Company is a “shell company” or indicate to the contrary to the SEC or any other Person; (iii) the Company shall
take all other action under its control necessary to ensure the availability of Rule 144 under the 1933 Act for the sale of Shares by a Buyer at the earliest possible date; and (iv) the Company shall at all times while any Securities are
outstanding maintain its engagement of an independent registered public accounting firm. Except as otherwise set forth in Transaction Documents, the Company shall take all action under its control necessary to obtain and to continue the listing and
trading of its Common Stock (including, without limitation, all Registrable Securities) on the OTC Markets, Inc. (“OTCM”) on the OTC Pink (“OTCP”), OTCQB (“OTCQB”), or OTCQX (“OTCQX”), and will comply in all
material respects with the Company’s reporting, filing and other obligations under the by-laws or rules of the Financial Industry Regulatory Authority (“FINRA”). If, so long as a Buyer beneficially owns any of the Securities, the
Company receives any written notice from the OTCM, FINRA, or the SEC with respect to either any alleged deficiency in the Company’s compliance with applicable rules and regulations (including without limitation any comments from the SEC on any
of the Company’s documents filed (or the failure to have made any such filing) under the 1933 Act or the Exchange Act) (each, a “Regulatory Notice”), then the Company shall promptly, and in any event within two (2) business days,
provide copies of the Regulatory Notice to the Buyers, and shall promptly, and in any event within five (5) business days of receipt of the Regulatory Notice (a “Regulatory Response”), respond in writing to the OTCM, FINRA and/or SEC
(as the case may be), setting forth the Company’s explanation and/or response to the issues raised in the Regulatory Notice, with a view towards maintaining and/or regaining full compliance with the applicable rules and regulations of the OTCM,
FINRA and/or SEC and maintaining or regaining good standing of the Company with the OTCM, FINRA and/or SEC, as the case may be, the intent being to ensure that the Company maintain its reporting company status with the SEC and that its Common Stock
be and remain available for trading on the OTCP, OTCQB, or OTCQX. Further, at all times while any Securities are outstanding, the Common Stock shall be DWAC Operational, and the Common Stock shall not be subject to any DTC “chill”
designation or similar restriction on the clearing of the Common Stock through DTC. 
 f. Use of Proceeds. The Company shall use the
proceeds from the sale of the Debentures for working capital purposes only subject to customary restrictions. Absent the prior written approval of a majority of the principal amount of the Debentures then outstanding, the Company shall not use any
portion of the proceeds of the sale of the Debentures to (i) repay any indebtedness or other obligation of the Company incurred prior to the date of this Agreement outside the normal course of business, (ii) pay any dividends or redemption
amount on any of the 

  
 13 













 
Company’s equity or equity equivalents, (iii) pay any amounts, whether on account of debt obligations of the Company or otherwise, except for compensation, to any officer, director or
other related party of the Company or (iv) pay deferred compensation or any compensation to any of the directors or officers of the Company in excess of the rate or amount paid or accrued during the fiscal year ended December 31, 2018 (as
base compensation and excluding any discretionary amounts), other than modest increases consistent with prior practice that are approved by the Company’s Board of Directors. 

g. [Intentionally Omitted]. 

h. Reimbursement. If (i) a Buyer becomes a party defendant in any capacity in any action or proceeding brought by any stockholder
of the Company, in connection with or as a result of the consummation of the transactions contemplated by the Transaction Documents, or if a Buyer is impleaded in any such action, proceeding or investigation by any Person, or (ii) the Buyer,
other than by reason of its own gross negligence, willful misconduct or breach of law (as adjudicated by a court of law having proper jurisdiction and such adjudication is not subject to appeal), becomes a party defendant in any capacity in any
action or proceeding brought by the SEC against or involving the Company or in connection with or as a result of the consummation of the transactions contemplated by the Transaction Documents, or if a Buyer is impleaded in any such action,
proceeding or investigation by any Person, then in any such case, the Company shall promptly reimburse the Buyer for its or their reasonable legal and other expenses (including the cost of any investigation and preparation) incurred in connection
therewith. The reimbursement obligations of the Company under this paragraph shall be in addition to any liability which the Company may otherwise have, shall extend upon the same terms and conditions to any affiliates of the Buyer who are actually
named in such action, proceeding or investigation, and partners, directors, agents, employees and controlling Persons (if any), as the case may be, of the Buyer, and any such Affiliate, and shall be binding upon and inure to the benefit of any
successors, assigns, heirs and personal representatives of the Company, the Buyer, and any such Affiliate and any such Person. Except as otherwise set forth in the Transaction Documents, the Company also agrees that neither any Buyer, nor any such
Affiliate, partners, directors, agents, employees or controlling Persons shall have any liability to the Company or any Person asserting claims on behalf of or in right of the Company in connection with or as a result of the consummation of the
Transaction Documents. 
 i. Legal Opinions. The Company shall provide the Transfer Agent and/or each Buyer, or their respective
brokerage and/or clearing firm with all relevant legal opinions and other documentation requested by a Buyer in connection with the issuance of the Conversion Shares or the Restricted Stock, or the sale thereof, to confirm the share issuance(s) such
that the Conversion Shares and/or Restricted Stock may be deposited with the applicable brokerage and/or clearing firm. 
 j.
[Intentionally Omitted]. 
 k. Notice of Material Adverse Effect. The Company shall notify each Buyer (and any subsequent
holder of the Debentures), as soon as practicable and in no event later than three (3) business days of the Company’s knowledge of any Material Adverse Effect on the Company. For purposes of the foregoing, “knowledge” means the
earlier of the Company’s actual knowledge or the Company’s constructive knowledge upon due inquiry. 

  
 14 













 l. Public Disclosure. Except to the extent required by applicable law, absent each
Buyer’s prior written consent, the Company shall not reference the name of the Buyer in any press release, securities disclosure, business plan, marketing or funding proposal. 

m. Nature of Transaction; Savings Clause. It is the parties’ express understanding and agreement that the transactions contemplated
by the Transaction Documents constitute an investment and not a loan. If nonetheless such transactions are deemed to be a loan (as adjudicated by a court of law having proper jurisdiction and such adjudication is not subject to appeal), the Company
shall not be obligated or required to pay interest at a rate that could subject Buyer to either civil or criminal liability as a result of such rate exceeding the maximum rate that the Buyer is permitted to charge under applicable law, and the
Company’s obligations under the Transaction Documents shall not be void or voidable on the basis of the Buyer’s lack of any license or registration as a lender with any governmental authority. It is expressly understood and agreed by the
parties that neither the amounts payable pursuant to Section 12, any redemption premium, remedy upon an Event of Default (as defined in the Debentures), original issue discount nor any investment returns of the Buyer on the sale of the
Debentures or the sale of any Conversion Shares (whether unrealized or realized) shall be construed as interest. If, by the terms of the Debentures, any other Transaction Document or any other instrument, Company is at any time required or obligated
to pay interest at a rate exceeding such maximum rate, interest payable under the Debenture and/or such other Transaction Documents or other instrument shall be computed (or recomputed) at such maximum rate, and the portion of all prior interest
payments (if any) exceeding such maximum shall be applied to payment of the outstanding principal of the Debentures. 
 5. TRANSFER
AGENT INSTRUCTIONS. 
 a. [Intentionally Omitted].  

b. Conversion.  

(i) The Company shall permit each Buyer to exercise the right to convert the Debentures by faxing, emailing or delivering overnight an executed
and completed Notice of Conversion to the Company or the Transfer Agent. If so requested by the Buyer or the Transfer Agent, the Company shall within one (1) business day respond with its endorsement so as to confirm the outstanding principal
amount of any Debenture submitted for conversion or shall reconcile any difference with the Buyer promptly after receiving such Notice of Conversion. 

(ii) The term “Conversion Date” means, with respect to any conversion elected by the holder of the Debentures, the date specified in
the Notice of Conversion, provided the copy of the Notice of Conversion is given either via mail or facsimile to or otherwise delivered to the Transfer Agent and/or the Company in accordance with the provisions hereof so that it is received by the
Transfer Agent and/or the Company on or before such specified date. 

  
 15 













 (iii) The Company shall deliver (or will cause the Transfer Agent to deliver) the Conversion
Shares issuable upon conversion as follows: (1) if the Company is then DWAC Operational, via DWAC, (2) if the Common Stock is then eligible for the Depository Trust Company’s Direct Registration System (“DRS”), if so
requested by the Buyer, or (3) if the Company is not then DWAC Operational or the Common Stock is not then eligible for DRS, in certificated form, to the Buyer at the address specified in the Notice of Conversion (which may be the Buyer’s
address for notices as contemplated by Section 10 hereof or a different address) via express courier, in each case within two (2) business days (the “Delivery Date”) after (A) the business day on which the Company or the
Transfer Agent has received the Notice of Conversion (by facsimile, email or other delivery) or (B) the date on which payment of interest and principal on the Debentures, which the Company has elected to pay by the issuance of Common Stock, as
contemplated by the Debentures, was due, as the case may be. 
 c. Failure to Timely Issue Conversion Shares or De-Legended Shares.
The Company’s failure to issue and deliver Conversion Shares to the Buyer (either by DWAC, DRS or in certificated form, as required by Section 5(b)) on or before the Delivery Date shall be considered an Event of Default, which shall
entitle the Buyer to certain remedies set forth in the Debentures and provided by applicable law. Similarly, the Company’s failure to issue and deliver Common Stock in unrestricted form without a restrictive legend when required under
the Transaction Documents shall entitle the Buyer to damages for the diminution in value (if any) of the relevant shares between the date delivery was due versus the date ultimately delivered in unrestricted form. The Company acknowledges that its
failure to timely honor a Notice of Conversion (or the occurrence of any other Event of Default) shall cause definable financial hardship on the Buyer(s) and that the remedies set forth herein and in the Debentures are reasonable and appropriate.

 d. Duties of Company; Authorization. The Company hereby authorizes and agrees to authorize the Transfer Agent to correspond and
otherwise communicate with the Buyer or their representatives in connection with the foregoing and other matters related to the Common Stock. Further, the Company hereby authorizes the Buyer or its representative to provide instructions to the
Transfer Agent that are consistent with the foregoing and instructs the Transfer Agent to honor any such instructions. Should the Company fail for any reason to keep current in its payment obligations to the Transfer Agent, the Buyer may pay such
amounts as are necessary to compensate the Transfer Agent for performing its duties with respect to issuance of Conversion Shares and/or de-legending certificates representing Restricted Stock, and all amounts so paid shall be promptly reimbursed by
the Company. If not so reimbursed within thirty (30) days, such amounts shall, at the option of the Buyer and without prior notice to or consent of the Company, be added to the principal amount due under the Debenture(s) held by the Buyer,
whereupon interest will begin to accrue on such amounts at the rate specified in the Debentures. 
 e. Effect of Bankruptcy. Each
Buyer shall be entitled to exercise its conversion privilege with respect to the Debentures notwithstanding the commencement of any case under 11 U.S.C. §101 et seq. (the “Bankruptcy Code”). In the event the Company is a debtor
under the Bankruptcy Code, the Company hereby waives, to the fullest extent permitted, any rights to relief it may have under 11 U.S.C. §362 in respect of each Buyer’s conversion privilege. The Company hereby waives, to the fullest extent
permitted, any rights to relief it may have under 11 U.S.C. §362 in respect of the conversion of the Debentures. The Company agrees, without cost or expense to a Buyer, to take or to consent to any and all action necessary to effectuate relief
under 11 U.S.C. §362. 

  
 16 













 6. CLOSINGS. 

a. Signing Closing. Promptly upon the execution and delivery of this Agreement, the Signing Debenture, and all conditions in Sections 7
and 8 herein are met (the “Signing Closing Date”), (A) the Company shall deliver to the Buyer the following: (i) the Signing Debenture; (ii) [Intentionally Omitted]; (iii) duly executed counterparts of the Transaction
Documents; and (iv) an officer’s certificate of the Company confirming the accuracy of the Company’s representations and warranties contained herein, and (B) each Buyer shall deliver to the Company the following: (i) their
respective Signing Purchase Price and (ii) duly executed counterparts of the Transaction Documents (as applicable). 
 b. Second
Closing. At any time after thirty (30) days following the Signing Closing Date, subject to the mutual agreement of the Buyer and the Company, for the “Second Closing Date” and subject to satisfaction of the conditions set forth in
Sections 7 and 8, (A) the Company shall deliver to the Buyers the following: (i) the Second Debenture; (ii) [Intentionally Omitted]; and (iii) an officer’s certificate of the Company confirming, as of the Second Closing
Date, the accuracy of the Company’s representations and warranties contained herein and updating Schedules 3(b), 3(c) and 3(k) as of the Second Closing Date, and (B) each Buyer shall deliver to the Company their respective
Second Purchase Price. 
 c. [Intentionally Omitted]. 

d. Location and Time of Closings. Each Closing shall be deemed to occur on the related Closing Date at the office of the Buyer’s
counsel and shall take place no later than 5:00 P.M., east coast time, on such day or such other time as is mutually agreed upon by the Company and the Buyer. 

7. CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL. 

The Company’s obligation to sell the Debentures to each Buyer pursuant to this Agreement on each Closing Date is conditioned upon: 

a. Purchase Price. Delivery to the Company of good funds as payment in full of the respective Purchase Price for the Debentures at each
Closing in accordance with this Agreement; 
 b. Representations and Warranties; Covenants. The accuracy on the Closing Date of the
representations and warranties of the Buyer contained in this Agreement, each as if made on such date, and the performance by the Buyer on or before such date of all covenants and agreements of the Buyer required to be performed on or before such
date; and 

  
 17 













 c. Laws and Regulations; Consents and Approvals. There shall not be in effect any
law, rule or regulation prohibiting or restricting the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained. 

8. CONDITIONS TO THE BUYER’S OBLIGATION TO PURCHASE. 

Each Buyer’s obligation to purchase the Debentures at each Closing is conditioned upon: 

a. Transaction Documents. The execution and delivery of this Agreement by the Company; 

b. Debenture(s). Delivery by the Company to the Buyer of the Debentures to be purchased in accordance with this Agreement; 

c. Section 4(2) Exemption. The Debentures and the Conversion Shares shall be exempt from registration under the 1933 Act, pursuant
to Section 4(2) thereof; 
 d. DWAC Status. The Common Stock shall be DWAC Operational;  

e. Representations and Warranties; Covenants. The accuracy in all material respects on the Closing Date of the representations and
warranties of the Company contained in this Agreement, each as if made on such date, and the performance by the Company on or before such date of all covenants and agreements of the Company required to be performed on or before such date; 

f. Good-faith Opinion. It should be the Buyer’s reasonable belief that (i) no Event of Default under the terms of any
outstanding indebtedness of the Company shall have occurred or would likely occur with the passage of time and (ii) no material adverse change in the financial condition or business operations of the Company shall have occurred; 

g. Legal Proceedings. There shall be no litigation, criminal or civil, regulatory impairment or other legal and/or administrative
proceedings challenging or seeking to limit the Company’s ability to issue the Securities or the Common Stock; 
 h. [Reserved]; 

i. Corporate Resolutions. Delivery by the Company to the Buyer a copy of resolutions of the Company’s board of directors, approving
and authorizing the execution, delivery and performance of the Transaction Documents and the transactions contemplated thereby in the form attached hereto as Exhibit C (the “Irrevocable Resolutions”); 

j. Officer’s Certificate. Delivery by the Company to the Buyer of a certificate of the Chief Executive Officer of the Company in
the form attached hereto as Exhibit D; 
 k. Search Results. Delivery by the Company to the Buyer of copies of UCC search
reports, issued by the Secretary of State of the state of incorporation of the Company and each Subsidiary, dated such a date as is reasonably acceptable to Buyer, listing all effective financing statements which name the Company or Subsidiary (as
applicable), under its present name and any previous names, as debtor, together with copies of such financing statements; 

  
 18 













 l. Certificate of Good Standing. Delivery by the Company to the Buyer of a copy of a
certificate of good standing with respect to the Company, issued by the Secretary of State of the state of incorporation of the Company, dated such a date as is reasonably acceptable to Buyer, evidencing the good standing thereof; 

m. Laws and Regulations; Consents and Approvals. There shall not be in effect any law, rule or regulation prohibiting or restricting the
transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained; and 
 n. Adverse Changes.
From and after the date hereof to and including each Closing Date, (i) the trading of the Common Stock shall not have been suspended by the SEC, FINRA, or any other governmental or self-regulatory organization, and trading in securities
generally on OTCM shall not have been suspended or limited, nor shall minimum prices been established for securities traded on the OTCM; (ii) there shall not have occurred any outbreak or escalation of hostilities involving the United States or
any material adverse change in any financial market that in either case in the reasonable judgment of the Buyer makes it impracticable or inadvisable to purchase the Debentures. 

o. [Intentionally Omitted].  

p. Acquisition of Oncotelic, Inc. The Company shall have fully consummated its acquisition of Oncotelic, Inc. (the “Target”),
including but not limited to the satisfaction of all conditions contained in all of the transaction documents, that have been or will be entered into between the Company and the Target, related to the acquisition of the Target. 

9. GOVERNING LAW; MISCELLANEOUS. 

a. MANDATORY FORUM SELECTION. ANY DISPUTE ARISING UNDER, RELATING TO, OR IN CONNECTION WITH THE AGREEMENT OR RELATED TO ANY MATTER WHICH
IS THE SUBJECT OF OR INCIDENTAL TO THE AGREEMENT (WHETHER OR NOT SUCH CLAIM IS BASED UPON BREACH OF CONTRACT OR TORT) SHALL BE SUBJECT TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE STATE AND/OR FEDERAL COURTS LOCATED IN MIAMI-DADE COUNTY,
FLORIDA. THIS PROVISION IS INTENDED TO BE A “MANDATORY” FORUM SELECTION CLAUSE AND GOVERNED BY AND INTERPRETED CONSISTENTLY WITH FLORIDA LAW. 

b. Governing Law. Except in the case of the Mandatory Forum Selection clause above, this Agreement shall be delivered and accepted in
and shall be deemed to be contracts made under and governed by the internal laws of the State of Nevada, and for all purposes shall be construed in accordance with the laws of the State of Nevada, without giving effect to the choice of law
provisions. To the extent determined by the applicable court described above, the Company shall reimburse the Buyer for any reasonable legal fees and disbursements incurred by the Buyer in enforcement of or protection of any of its rights under any
of the Transaction Documents. 

  
 19 













 c. Waivers. Failure of any party to exercise any right or remedy under this Agreement
or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof. 
 d. Successors and
Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto. 
 e.
Construction. All pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as the context may require. 

f. Facsimiles; E-mails. A facsimile or email transmission of this signed Agreement or a Notice of Conversion under the Debentures shall
be legal and binding on all parties hereto. Such electronic signatures shall be the equivalent of original signatures. 
 g.
Counterparts. This Agreement may be signed in one or more counterparts, each of which shall be deemed an original. 
 h.
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. 

i. Enforceability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability of this Agreement in any other jurisdiction. 

j. Amendment. This Agreement may be amended only by the written consent of a majority in interest of the holders of the Debentures and
an instrument in writing signed by the Company. 
 k. Entire Agreement. This Agreement, together with the other Transaction Documents,
supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter hereof. 
 l. No Strict
Construction. This Agreement shall be construed as if both Parties had equal say in its drafting, and thus shall not be construed against the drafter. 

m. Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby. 

  
 20 













 10. NOTICES. 

Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given
on the earliest of: 
 a. the date delivered, if delivered by personal delivery as against written receipt therefor or by confirmed facsimile
or email transmission, 
 b. the third (3rd) business day after deposit, postage
prepaid, in the United States Postal Service by registered or certified mail, or 
 c. the first (1st) business day after deposit with a recognized courier service (e.g. FedEx, UPS, DHL, US Postal Service) for delivery by next-day express courier, with delivery costs and fees prepaid, 

in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate by
ten (10) days’ advance written notice similarly given to each of the other parties hereto): 
  

			
	COMPANY:	  	 Mateon Therapeutics, Inc.
 701 Gateway Blvd.,
Suite 210
 South San Francisco, CA 94080
 Attention: William
Schwieterman, Chief Executive Officer
 Email: 

		
		  	 With copies to (which shall not constitute notice):
  

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
 One Financial
Center
 Boston, MA 02111
 Attention: Megan Gates,
Esq.
 Email: 

		
	BUYER:	  	To the address set forth below their signature on the signature page
		
		  	With copies to (which shall not constitute notice):
		
		  	 Sheppard Mullin Richter & Hampton LLP
 12275
El Camino Real, Suite 200
 San Diego CA, 92130
 Attention:
James A. Mercer III, Esq.
 Email: 


 11. SURVIVAL OF REPRESENTATIONS AND WARRANTIES. The Company’s representations and warranties
herein shall survive for so long as any Debentures are outstanding, and shall inure to the benefit of the Buyer, its successors and assigns. 

  
 21 













 12. FEES; EXPENSES. 

a. [Intentionally Omitted].  

b. [Intentionally Omitted].  

[Signature Page Follows] 

  
 22 













 IN WITNESS WHEREOF, this Agreement has been duly executed by the Buyer and the
Company as of the date first set forth above. 
  

			
	COMPANY:
	
	MATEON THERAPEUTICS, INC.
		
	By:	 	 
	Name:	 	William Schwieterman
	Title:	 	Chief Executive Officer
	
	BUYER:
		
		 	 
		 	Name: Vuong Trieu
		 	Address:
		
		 	 
		 	Name: 
		 	Address:


 [Signature Page to Securities Purchase Agreement] 












 EXHIBITS 

 

			
	Exhibit A	  	FORM OF DEBENTURE
		
	Exhibit B	  	[INTENTIONALLY OMITTED]
		
	Exhibit C	  	FORM OF RESOLUTIONS OF THE BOARD OF DIRECTORS
		
	Exhibit D	  	FORM OF OFFICER’S CERTIFICATE